You are here

FDA OKs Device for Treating Gastrointestinal Bleeding

Approval based on clinical studies and real-world evidence

The FDA has permitted marketing of Hemospray (Wilson-Cook Medical, Inc.), a new device used to help control certain types of bleeding in the gastrointestinal (GI) tract.

“The device provides an additional nonsurgical option for treating upper and lower GI bleeding in certain patients and may help reduce the risk of death from a GI bleed for many patients,” said Binita Ashar, MD, Director of the Division of Surgical Devices in the FDA’s Center for Devices and Radiological Health.

GI bleeding can occur in the upper GI tract (esophagus, stomach, or small intestine) or the lower GI tract (colon and rectum). Causes of GI bleeding include gastric ulcers, artery or vein (arteriovenous) malformations, diverticulosis, cancer, or inflammatory bowel disease. Older patients are at a higher risk of death from severe GI bleeding. 

The Hemospray device is intended to treat most types of upper or lower GI bleeding. The device is an aerosolized spray that delivers a mineral blend to the bleeding site. The device is applied during an endoscopic procedure and can cover large areas, such as large ulcers or tumors. The device is not intended for use in patients with variceal bleeding, which is bleeding that comes from enlarged veins that develop in certain medical conditions like alcoholic liver disease.

The FDA reviewed data from clinical studies consisting of 228 patients with upper and lower GI bleeding, supplemented with real-world evidence from medical literature reports including an additional 522 patients. The Hemospray device stopped GI bleeding in 95% of patients within five minutes of device usage. Re-bleeding, usually within 72 hours, but up to 30 days following device usage, was observed in 20% of these patients. One serious side effect, bowel perforation, was observed in approximately 1% of patients. Hemospray is contraindicated in patients who have a gastrointestinal fistula or are at high risk for experiencing a gastrointestinal perforation.

The FDA reviewed the Hemospray device through the de novo premarket review pathway, a regulatory pathway for some low- to moderate-risk devices of a new type.

Source: FDA; May 7, 2018.

More Headlines

COMPASS Trial Shows 24% Reduction in Major CV Events
Only 18.7% of Patients Treated Had Uveitis Recurrence
Protein Organizes and Stores DNA for B Cells in Methodical Fashion
Patients’ Bodies Most Common Source of Hospital-Acquired Bloodstream Infections
Growing opioid crisis fueling suicide increase according to study
Vaccine Prevents Some Cancers, Diseases Caused by 9 HPV Types
In Future, Providers May Screen for APOE4 Before Treatment 
MIT Professor Working to Produce Thousands of Drugs on Demand
Agency Scrutinizes Attempts to Block Generics